Myositis

• 

  Subject Areas on Research

  • 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. 
  • 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. 
  • A 55-year-old man with fever, renal failure, and hip pain. 
  • A Path to Prediction of Outcomes in Juvenile Idiopathic Inflammatory Myopathy. 
  • A comparative study of the effect of arterial and venous occlusion after various periods of ischemia. 
  • Association of Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies With DRB1*07:01 and Severe Myositis in Juvenile Myositis Patients. 
  • Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab. 
  • Automatic analysis of the electromyographic interference pattern. Part II: Findings in control subjects and in some neuromuscular diseases. 
  • BAFF expression correlates with idiopathic inflammatory myopathy disease activity measures and autoantibodies. 
  • Causes of creatine kinase levels greater than 1000 IU/L in patients referred to rheumatology. 
  • Chimerism in myositis. 
  • Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. 
  • Dendritic cells and the immunopathogenesis of idiopathic inflammatory myopathies. 
  • Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. 
  • Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group. 
  • Effects of HMGB1 on in vitro responses of isolated muscle fibers and functional aspects in skeletal muscles of idiopathic inflammatory myopathies. 
  • Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. 
  • Evaluation of muscles affected by myositis using magnetic resonance elastography. 
  • Evaluation of penicillin and hyperbaric oxygen in the treatment of streptococcal myositis. 
  • Extracellular matrix disruption and pain after eccentric muscle action. 
  • Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. 
  • Gemcitabine-induced radiation recall myositis. 
  • Genetic and environmental risk factors for idiopathic inflammatory myopathies. 
  • Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes. 
  • HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. 
  • Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management. 
  • Index of suspicion. 
  • Interesting image. F-18 fluorodeoxyglocose positron emission tomography/computed tomography in the diagnosis of chronic myopathic sarcoidosis. 
  • Interferon-regulated chemokine score associated with improvement in disease activity in refractory myositis patients treated with rituximab. 
  • International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. 
  • International consensus on preliminary definitions of improvement in adult and juvenile myositis. 
  • International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. 
  • Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. 
  • Managing contraception and pregnancy in the rheumatologic diseases. 
  • Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. 
  • Myositis in children. 
  • Necrotizing fasciitis and myositis caused by group A streptococci. Epidemiology, diagnosis, and treatment of "flesh-eating bacteria". 
  • Necrotizing myofasciitis: an atypical cause of "acute abdomen" in an immunocompromised child. 
  • Normal scores for nine maneuvers of the Childhood Myositis Assessment Scale. 
  • Pectoralis pyomyositis: an unusual cause of chest wall pain in a patient with diabetes mellitus and rheumatoid arthritis. 
  • Phenotype standardization for statin-induced myotoxicity. 
  • Polymyositis after propylthiouracil treatment for hyperthyroidism. 
  • Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis. 
  • Profound muscle weakness and hypokalemia due to clay ingestion. 
  • Pyomyositis and polyarticular septic arthritis from Hemophilus influenzae in a nonimmunocompromised adult. 
  • Pyomyositis in a temperate climate. Presentation, diagnosis, and treatment. 
  • Pyomyositis: characteristics at CT and MR imaging. 
  • Quantitative EMG in inflammatory myopathy. 
  • Real world utilization of the myositis autoantibody panel. 
  • Recent advances in juvenile idiopathic inflammatory myopathies. 
  • Rheumatologic manifestations of cancer. 
  • STAT3 Regulates Self-Renewal of Adult Muscle Satellite Cells during Injury-Induced Muscle Regeneration. 
  • Spontaneous pyomyositis in a patient with Felty's syndrome: diagnosis using computerized tomography. 
  • Systematic protein-protein interaction and pathway analyses in the idiopathic inflammatory myopathies. 
  • The inflammatory milieu in idiopathic inflammatory myositis. 
  • Update on outcome assessment in myositis. 
  • Update: biomarkers for idiopathic inflammatory myopathies. 
  • Utility of patient-reported outcomes measurement information system (PROMIS) physical function form in inflammatory myopathy. 
  • Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. 
• 

  Keywords of People

  • Allen, Nancy Bates, Professor Emeritus of Medicine, Medicine, Rheumatology and Immunology
  • Dvergsten, Jeffrey Arthur, Associate Professor of Pediatrics, Pediatrics, Rheumatology
  • Gonzalez, Natalia Laura, Assistant Professor of Neurology, Neurology, Neuromuscular Disease